Back to Authors

Chattha, Asma J

Mayo Clinic

Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.

Citations 2

Oral Contraceptive Use in Obese Adolescents: A Cautionary Tale
Chattha, Asma , Rodriguez, Vilmarie , Chattha, Asma J, Warad, Deepti

Journal of Pediatric Hematology/Oncology | January 14, 2021 | Volume: 43 | Issue: 8 | Pages: e1124-e1127

10.1097/mph.0000000000002053 Get It

Venous thromboembolism (VTE) is a life-threatening complication rarely encountered with the use of combined oral contraceptives (COCs). Obesity is an additional thrombosis risk factor that has been shown to further increase the risk of VTE with the use of COCs. We present 5 cases of obese adolescents (body mass index >30 kg/m2) who encountered thrombosis complications while on COCs. Although the absolute risk of VTE events in the setting of COCs is rare, caution should be observed when choosing hormonal therapy and safer COCs alternatives discussed with adolescents who are obese.
Autoimmune progesterone dermatitis in the adolescent population
Aghazadeh, Nessa , Chattha, Asma , Hartz, Martha F., Davis, Dawn Marie R. , Chattha, Asma J, Davis, Dawn M R , Aghazadeh Mohandesi, Nessa

Pediatric Dermatology | December 27, 2020 | Volume: 38 | Issue: 2 | Pages: 380-384

10.1111/pde.14423 Get It

AbstractBackground/ObjectiveAutoimmune progesterone dermatitis (APD) is a rare autoimmune hypersensitivity reaction that occurs cyclically at the peak of endogenous progesterone production during the menstrual cycle in women. No study characterizing APD in the adolescent population is found; it appears likely to be underdiagnosed and undertreated.MethodsA retrospective, single‐center, review of all adolescent and pediatric patients (<20 years old at onset) with documented diagnosis of APD.ResultsSeventeen adolescent APD patients were included (mean age at diagnosis: 14.4 ± 2 years, mean interval of 13.6 ± 11.1 months between symptom onset and diagnosis). Twelve patients presented with urticaria, two with fixed drug eruption. Erythema multiforme, eczema, and recurrent aphthous stomatitis were present in one patient each. Exposure to exogenous progestin was present in two patients prior to disease onset. Progesterone skin test was performed in six patients with positive results in two. Fourteen patients received antihistamines and/or a topical corticosteroid. Combined oral contraceptives (COCs) were given to eleven patients, in seven via continuous daily dosing. Gonadotropin‐releasing hormone agonist (GnRHa) was used in five, progesterone desensitization in four, omalizumab in two, and danazol in one patient.ConclusionsAdolescent APD is associated with a significant delay in diagnosis. The most common manifestation is urticaria. Exogenous exposure to progestins is uncommon in adolescent APD. Continuous COC, GnRHa, and progesterone desensitization have been used to control symptoms. Large, multicenter studies are required to better define, diagnose, and treat this under recognized condition among adolescent patients.